| MeSH term | MeSH ID | Detail |
|---|---|---|
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Postoperative Complications | D011183 | 5 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Neoplasm Recurrence, Local | D009364 | 5 associated lipids |
| Osteonecrosis | D010020 | 5 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Heart Failure | D006333 | 36 associated lipids |
| Angioedema | D000799 | 6 associated lipids |
| Fractures, Spontaneous | D005598 | 4 associated lipids |
| Hydronephrosis | D006869 | 4 associated lipids |
| Trypanosomiasis | D014352 | 5 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Liver Diseases | D008107 | 31 associated lipids |
| Corneal Diseases | D003316 | 13 associated lipids |
| Testicular Diseases | D013733 | 15 associated lipids |
| Facial Dermatoses | D005148 | 7 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Bens G et al. | Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. | 2003 | Br. J. Dermatol. | pmid:12890237 |
| Reich K et al. | Topical tacrolimus for pyoderma gangrenosum. | 1998 | Br. J. Dermatol. | pmid:9892935 |
| Kyllönen H et al. | Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. | 2004 | Br. J. Dermatol. | pmid:15214906 |
| Danby SG and Cork MJ | The effects of pimecrolimus on the innate immune response in atopic dermatitis. | 2013 | Br. J. Dermatol. | pmid:23362967 |
| Schmitt J et al. | Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. | 2011 | Br. J. Dermatol. | pmid:20819086 |
| Schauber J et al. | Topical treatment of perianal eczema with tacrolimus 0.1%. | 2009 | Br. J. Dermatol. | pmid:19575757 |
| Rustin MH | The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. | 2007 | Br. J. Dermatol. | pmid:17854353 |
| Bunker CB | Male genital lichen sclerosus and tacrolimus. | 2007 | Br. J. Dermatol. | pmid:17854373 |
| Remitz A et al. | Tacrolimus ointment improves psoriasis in a microplaque assay. | 1999 | Br. J. Dermatol. | pmid:10417522 |
| Braza TJ et al. | Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. | 2003 | Br. J. Dermatol. | pmid:12828755 |
| Vidal D and Alomar A | Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:14996128 |
| Lan CC et al. | FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. | 2011 | Br. J. Dermatol. | pmid:21039414 |
| Kanekura T et al. | Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. | 2003 | Br. J. Dermatol. | pmid:12588393 |
| Vente C et al. | Erosive mucosal lichen planus: response to topical treatment with tacrolimus. | 1999 | Br. J. Dermatol. | pmid:10233234 |
| Lyon CC et al. | Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. | 1999 | Br. J. Dermatol. | pmid:10233300 |
| Jolles S et al. | Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. | 1999 | Br. J. Dermatol. | pmid:10233301 |
| Walker SL et al. | The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. | 2002 | Br. J. Dermatol. | pmid:12174136 |
| Anstey A | Therapeutic advances and shift in disease paradigm for atopic dermatitis. | 2008 | Br. J. Dermatol. | pmid:19036027 |
| Katoh N et al. | Cutaneous sarcoidosis successfully treated with topical tacrolimus. | 2002 | Br. J. Dermatol. | pmid:12100200 |
| McElwee KJ et al. | Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. | 1997 | Br. J. Dermatol. | pmid:9390322 |
| Harper J et al. | First experience of topical SDZ ASM 981 in children with atopic dermatitis. | 2001 | Br. J. Dermatol. | pmid:11298537 |
| Luger T et al. | SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. | 2001 | Br. J. Dermatol. | pmid:11298538 |
| Lan CC et al. | FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. | 2004 | Br. J. Dermatol. | pmid:15377358 |
| Piram M et al. | Short- and long-term outcome of linear morphoea in children. | 2013 | Br. J. Dermatol. | pmid:24032480 |
| Reitamo S et al. | 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. | 2004 | Br. J. Dermatol. | pmid:15030341 |
| Chuh AA | The application of topical tacrolimus in vesicular pemphigoid. | 2004 | Br. J. Dermatol. | pmid:15030368 |
| Gollnick H et al. | Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. | 2008 | Br. J. Dermatol. | pmid:18341665 |
| Erdogan M et al. | Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. | 2002 | Br. J. Dermatol. | pmid:12072063 |
| Hjelmgren J et al. | Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. | 2007 | Br. J. Dermatol. | pmid:17263826 |
| Volz T et al. | Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. | 2008 | Br. J. Dermatol. | pmid:18647310 |
| Rigopoulos D et al. | Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. | 2009 | Br. J. Dermatol. | pmid:19120329 |
| Oranje AP et al. | Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. | 2009 | Br. J. Dermatol. | pmid:18795918 |
| Wataya-Kaneda M et al. | A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. | 2011 | Br. J. Dermatol. | pmid:21692771 |
| Spergel JM et al. | Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. | 2007 | Br. J. Dermatol. | pmid:17573885 |
| Niwa Y et al. | Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. | 2003 | Br. J. Dermatol. | pmid:14632799 |
| Ko MJ and Chu CY | Topical tacrolimus therapy for localized bullous pemphigoid. | 2003 | Br. J. Dermatol. | pmid:14632824 |
| Böhm M et al. | Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. | 2004 | Br. J. Dermatol. | pmid:15327576 |
| Langeland T and Engh V | Topical use of tacrolimus and squamous cell carcinoma on the penis. | 2005 | Br. J. Dermatol. | pmid:15656830 |
| Kreuter A et al. | Pimecrolimus 1% cream for perianal atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15656832 |
| Fiorentino DF et al. | The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. | 2011 | Br. J. Dermatol. | pmid:21166661 |
| Brouard MC et al. | Erosive pustular dermatosis of the leg: report of three cases. | 2002 | Br. J. Dermatol. | pmid:12366427 |
| Lewis FM and Neill SM | Safety of calcineurin inhibitors in the management of lichen sclerosis. | 2007 | Br. J. Dermatol. | pmid:17535239 |
| Connolly M and Kennedy C | Exfoliative cheilitis successfully treated with topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15270904 |
| Healy E et al. | Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. | 2011 | Br. J. Dermatol. | pmid:21083544 |
| Hengge UR et al. | Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. | 2006 | Br. J. Dermatol. | pmid:17034535 |
| Kang HY and Choi YM | FK506 increases pigmentation and migration of human melanocytes. | 2006 | Br. J. Dermatol. | pmid:17034537 |
| Lübbe J and Sorg O | Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. | 2004 | Br. J. Dermatol. | pmid:15606530 |
| Tzung TY et al. | Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. | 2007 | Br. J. Dermatol. | pmid:17199600 |
| Lonowski S et al. | Vitiligo: a potential autoimmune sequela of DRESS syndrome. | 2016 | Br. J. Dermatol. | pmid:27038429 |
| Gottlieb AB et al. | Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. | 2005 | Br. J. Dermatol. | pmid:15948985 |
| Bhol KC and Schechter PJ | Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948987 |
| Reitamo S et al. | A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948994 |
| Bos JD | Topical tacrolimus and pimecrolimus are not associated with skin atrophy. | 2002 | Br. J. Dermatol. | pmid:11903264 |
| Wolff K et al. | Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. | 2005 | Br. J. Dermatol. | pmid:15948996 |
| Rigopoulos D et al. | Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. | 2005 | Br. J. Dermatol. | pmid:15949015 |
| Kirtschig G et al. | Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. | 2002 | Br. J. Dermatol. | pmid:12207624 |
| Feldmann KA et al. | Is topical tacrolimus effective in alopecia areata universalis? | 2002 | Br. J. Dermatol. | pmid:12410729 |
| Sigurgeirsson B and Luger T | A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response. | 2017 | Br. J. Dermatol. | pmid:28940181 |
| Pereira U et al. | Mechanisms of the sensory effects of tacrolimus on the skin. | 2010 | Br. J. Dermatol. | pmid:20302583 |
| Ho N et al. | A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. | 2011 | Br. J. Dermatol. | pmid:21457214 |
| Rigopoulos D et al. | Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. | 2006 | Br. J. Dermatol. | pmid:16792767 |
| Weissenbacher S et al. | Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. | 2007 | Br. J. Dermatol. | pmid:17493072 |
| Williams HC | Preventing eczema flares with topical corticosteroids or tacrolimus: which is best? | 2011 | Br. J. Dermatol. | pmid:21271989 |
| Chohan R et al. | Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. | 2003 | Br. J. Haematol. | pmid:14510951 |
| Mehta RS et al. | Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. | 2016 | Br. J. Haematol. | pmid:26947769 |
| Pulsipher MA et al. | A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). | 2009 | Br. J. Haematol. | pmid:19744131 |
| Murata M et al. | A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. | 1999 | Br. J. Haematol. | pmid:10354150 |
| Armand P et al. | The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. | 2016 | Br. J. Haematol. | pmid:26729448 |
| Wong R et al. | Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. | 2003 | Br. J. Haematol. | pmid:12823354 |
| Feliu J et al. | Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. | 2014 | Br. J. Haematol. | pmid:24962133 |
| Couriel DR et al. | Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. | 2005 | Br. J. Haematol. | pmid:16042691 |
| Mollee P et al. | Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. | 2001 | Br. J. Haematol. | pmid:11328304 |
| Kida A et al. | Calcineurin-inhibitor pain syndrome following haematopoietic stem cell transplantation. | 2004 | Br. J. Haematol. | pmid:15257699 |
| Boulad F et al. | Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. | 2000 | Br. J. Haematol. | pmid:11167755 |
| Dusting GJ et al. | Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. | 1999 | Br. J. Pharmacol. | pmid:10510443 |
| Quintá HR and Galigniana MD | The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. | 2012 | Br. J. Pharmacol. | pmid:22091865 |
| Gil V et al. | Effects of inhibitors of hydrogen sulphide synthesis on rat colonic motility. | 2011 | Br. J. Pharmacol. | pmid:21486289 |
| Klettner A and Herdegen T | The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. | 2003 | Br. J. Pharmacol. | pmid:12642403 |
| Magari K et al. | Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. | 2003 | Br. J. Pharmacol. | pmid:12839866 |
| Simon N et al. | Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. | 2003 | Br. J. Pharmacol. | pmid:12540528 |
| Øzbay LA et al. | Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. | 2011 | Br. J. Pharmacol. | pmid:20825407 |
| Bader A et al. | Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. | 2000 | Br. J. Pharmacol. | pmid:10694240 |
| Squadrito F et al. | Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. | 1999 | Br. J. Pharmacol. | pmid:10385251 |
| Price RD et al. | FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. | 2003 | Br. J. Pharmacol. | pmid:14559856 |
| Hortelano S et al. | Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. | 1999 | Br. J. Pharmacol. | pmid:10205001 |
| Harrison S et al. | Stimulation of airway sensory nerves by cyclosporin A and FK506 in guinea-pig isolated bronchus. | 1998 | Br. J. Pharmacol. | pmid:9884067 |
| Eum SY et al. | Inhibition by the immunosuppressive agent FK-506 of antigen-induced airways eosinophilia and bronchial hyperreactivity in mice. | 1997 | Br. J. Pharmacol. | pmid:9117088 |
| Deters M et al. | Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. | 2002 | Br. J. Pharmacol. | pmid:12055139 |
| MacMillan D and McCarron JG | Regulation by FK506 and rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR. | 2009 | Br. J. Pharmacol. | pmid:19785652 |
| Waschulewski IH et al. | Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. | 1993 | Br. J. Pharmacol. | pmid:7683567 |
| Weidelt T and Isenberg G | Augmentation of SR Ca(2+) release by rapamycin and FK506 causes K(+)-channel activation and membrane hyperpolarization in bladder smooth muscle. | 2000 | Br. J. Pharmacol. | pmid:10742283 |
| Bas E et al. | Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. | 2012 | Br. J. Pharmacol. | pmid:22320124 |
| Gardiner SM et al. | Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. | 2004 | Br. J. Pharmacol. | pmid:14744807 |
| Pahl A et al. | Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. | 2002 | Br. J. Pharmacol. | pmid:11959794 |
| Sakuma S et al. | FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. | 2000 | Br. J. Pharmacol. | pmid:10928971 |
| Harrison CA et al. | Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. | 2007 | Br. J. Pharmacol. | pmid:17200674 |
| Zuany-Amorim C et al. | Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. | 1993 | Br. J. Pharmacol. | pmid:7694762 |
| Lampen A et al. | Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. | 1996 | Br. J. Pharmacol. | pmid:8732283 |
| Li J et al. | Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. | 2005 | Br. J. Pharmacol. | pmid:15821752 |
| Oetjen E et al. | The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level. | 2005 | Br. J. Pharmacol. | pmid:15711594 |